Headline News

 

Enhertu shows 14.3-month median progression-free survival as first-line therapy for HER2-mutant lung cancer in DESTINY-Lung04 trial

Posted on September 14, 2026

Gilead unveils new Foster City facility dedicated to oncology, inflammation, and data science research

Posted on September 14, 2026

Abbott’s TactiFlex Duo ablation catheter wins FDA approval for treating abnormal heart rhythms

Posted on September 14, 2026

GSK secures Japanese approval for prefilled syringe version of Shingrix

Posted on September 14, 2026

GSK unveils positive registrational data that could expand Jideytro into first line treatment for ROS1-positive non small cell lung cancer

Posted on September 14, 2026

WCLC 2026 presentations spotlight fresh survival gains and improved treatment tolerability across RYBREVANT EGFR-mutated lung cancer regimens

Posted on September 14, 2026

Atogepant meets all primary and secondary endpoints in Phase III menstrual migraine study

Posted on September 14, 2026

Ris Rez cuts risk of death by 54% in Phase III relapsed small cell lung cancer trial

Posted on September 14, 2026

Imfinzi plus Imdelltra improves survival in Phase III extensive stage small cell lung cancer trial

Posted on September 12, 2026

Etcamah combination misses primary endpoint in Phase III SERENA 4 breast cancer trial

Posted on September 12, 2026

Ascendis reports first infant data for once weekly TransCon CNP in achondroplasia

Posted on September 11, 2026

FDA grants Priority Review to Enspryng for MOGAD following Phase III results

Posted on September 11, 2026

FDA clears Bayer’s sevabertinib for first line HER2 mutant lung cancer

Posted on September 11, 2026

Johnson & Johnson gains CE Mark for ACUVUE OASYS MAX reusable lens

Posted on September 11, 2026

Biocon secures 10 year pertuzumab supply partnership for Brazil’s public healthcare system

Posted on September 09, 2026